Fee-charging Standards for Reviewing the Registration of Western Medicines Article 5

Review fees for each Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Inspections for Western Medicines are as below:1. GMP inspections for Domestic pharmaceutical manufacturer:(1) Inspection for new establishment, relocation, expansion, resumption of operation, or addition of a new active pharmaceutical ingredient, dosage form, process operation, medicinal product: TWD 120,000; Additional fee of TWD 20,000 will be charged whenever there is an additional dosage form, biological drug, or active pharmaceutical ingredient (limited to one additional dosage form, product or process operation per application).(2) Follow-up inspection: TWD 120,000.(3) Review of a pharmaceutical manufacturer which produces both drugs and non-medical products: TWD 20,000; Additional fee of TWD 5,000 will be charged for a shared promise whenever there is an additional product.(4) Review of contract analysis application: TWD 10,000; Additional fee of TWD 20,000 will be charged whenever onsite inspection is needed.(5) Change of the medicament manufacturing license: TWD 10,000; If only involving changes in the pharmacist in charge of the manufacturing: TWD 2,500.2. GMP inspections for Foreign pharmaceutical manufacturers:(1) Review of a Plant Master File (PMF): TWD 120,000; Additional fee of TWD 20,000 will be charged when there is an additional dosage form, biological drug, active pharmaceutical ingredient or process operation (limited to two additional dosage forms, products or process operations per application).(2) Follow-up review: TWD 120,000.(3) Inspection on a site with a PMF approval: TWD 600,000; Inspection on a site without a PMF approval: TWD 700,000; the fee for Inspections listed above, inclusive of fee for documentation review (TWD 60,000) and on-site inspection (TWD 540,000 or 640,000).Additional fee will be charged as below when there is an additional dosage form, biological drug, active pharmaceutical ingredient or process operation (limited to one additional dosage form, product or process operation per application):A. Non-sterile products in the same premises, HVAC system and water system: TWD 35,000.B. Non-sterile products in the same premises, but with different HVAC system and water system: TWD 50,000.C. Sterile products in the same premises, but with different HVAC system or water system: TWD 88,000.D. Non-sterile products in the same premises, but with different HVAC system and water system: TWD 70,000.E. Sterile products in the same premises, but with different HVAC system and water system: TWD 105,000.F. Non-sterile products in different premises: TWD 105,000.G.Sterile products in different premises: TWD 105,000.(4) Follow-up inspection: TWD 600,000; Additional fee will be charged when there is an additional dosage form, biological drug, or active pharmaceutical ingredient shall apply mutatis mutandis the Item 3 of Subparagraph 2.(5) A change of Taiwan agent of GMP approval letter: TWD 20,000.(6) A change of GMP approval letter (shall be limited in items neither a change of Taiwan agent nor subjected to inspection, according to the Regulations of Medicament Manufacturer): TWD 10,000.(7) Application fee for GMP registration of foreign active pharmaceutical ingredient manufacturer (limited to five products per application): TWD 20,000.(8) A Change of active pharmaceutical ingredient GMP reference letter: TWD 2,500.3. GDP inspections for western medicine dealers:(1) Inspection for new establishment, relocation, expansion, resumption of operation, or addition of a new pharmaceuticals distribution practice: TWD 30,000.(2) Follw-up inspection: TWD 30,000.(3) A change of the western pharmaceuticals distribution license: TWD 2,500.
中文原文 西藥查驗登記審查費收費標準第5條
辦理西藥製造及運銷品質檢查者,每件應繳納之審查費如下:
一、國內西藥製造工廠檢查:
(一)新設、遷移、擴建、復業或增加原料藥、劑型、加工項目、品項之檢查,新臺幣十二萬元,每增加一個劑型、生物藥品品項、原料藥品項、加工項目,增加收費新臺幣二萬元(每案限增加一個劑型、品項或加工項目)。
(二)後續管理檢查,新臺幣十二萬元。
(三)藥廠兼製產品審查,新臺幣二萬元,共用廠房者,每增加一個產品增加收費新臺幣五千元。
(四)委託檢驗申請案審查,新臺幣一萬元,須實地查核者,增加實地查核費用新臺幣二萬元。
(五)藥物製造許可登記事項之變更,新臺幣一萬元,但僅涉及監製藥師變更者,則收費新臺幣二千五百元。
二、國外西藥製造工廠檢查:
(一)國外藥廠工廠資料審查,新臺幣十二萬元,每增加一個劑型、生物藥品品項、原料藥品項、加工項目,增加收費新臺幣二萬元(每案限增加二個劑型、品項或加工項目)。
(二)國外藥廠後續管理審查,新臺幣十二萬元。
(三)國外藥廠實地查核,藥廠之工廠資料經衛生福利部准予備查者,收費新臺幣六十萬元;工廠資料未經衛生福利部准予備查者,收費新臺幣七十萬元;其國外藥廠實地查核收費含文件審查新臺幣六萬元及實地查核新臺幣五十四萬元或新臺幣六十四萬元,每件每增加一個劑型、生物藥品品項、原料藥品項、加工項目,增加收費如下(每案限增加一個劑型、品項或加工項目):1.非無菌製劑之同一廠房、空調、水系統,加收新臺幣三萬五千元。
2.非無菌製劑之同一廠房不同空調或水系統,加收新臺幣五萬元。
3.無菌製劑之同一廠房不同空調或水系統,加收新臺幣八萬八千元。
4.非無菌製劑之同一廠房不同空調系統且不同水系統,加收新臺幣七萬元。
5.無菌製劑之同一廠房不同空調系統且不同水系統,加收新臺幣十萬五千元。
6.非無菌製劑之不同廠房,加收新臺幣十萬五千元。
7.無菌製劑之不同廠房,加收新臺幣十萬五千元。
(四)國外藥廠後續管理實地查核,新臺幣六十萬元,併新增劑型、生物藥品品項、原料藥品項查核者,其增加收費之規定準用前目。
(五)國外藥廠藥品優良製造準則(GoodManufacturingPractice,GMP)核備函代理權移轉,新臺幣二萬元。
(六)國外藥廠藥品優良製造準則(GoodManufacturingPractice,GMP)核備函登記事項變更(限代理權移轉以外事項且未涉須依藥物製造業者檢查辦法實施檢查者),新臺幣一萬元。
(七)國外原料藥廠之藥品優良製造準則(GoodManufacturingPractice,GMP)新廠登記(每案限申請五個新增品項)或後續管理審查,新臺幣二萬元。
(八)國外原料藥廠藥品優良製造準則(GoodManufacturingPractice,GMP)登記事項之變更,新臺幣二千五百元。
三、國內西藥販賣業者運銷品質檢查:
(一)新設、遷移、擴建、復業或增加運銷作業項目之檢查,新臺幣三萬元。
(二)後續管理檢查,新臺幣三萬元。
(三)西藥運銷許可登記事項之變更(未涉及運銷作業項目及貯存藥品之場所變更者),新臺幣二千五百元。

English translation for reference only; the Chinese text prevails. Not legal advice.